Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Nabriva Therapeutics plc (NBRV) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/31/2023 8-K Quarterly results
07/24/2023 8-K Quarterly results
07/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SEPARATION AND RELEASE OF CLAIMS AGREEMENT",
"SEPARATION AND RELEASE OF CLAIMS AGREEMENT",
"NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT",
"NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT"
06/01/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/20/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SEPARATION AND RELEASE OF CLAIMS AGREEMENT",
"SEPARATION AND RELEASE OF CLAIMS AGREEMENT",
"NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT",
"NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENT"
01/09/2023 8-K Termination of a Material Definitive Agreement, Cost Associated with Exit or Disposal Activities, Other Events, Financial Sta...
Docs: "Nabriva Therapeutics Provides Corporate Update"
11/28/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/04/2022 8-K Other Events  Interactive Data
09/16/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF NABRIVA THERAPEUTICS PUBLIC LIMITED COMPANY COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF NABRIVA THERAPEUTICS PUBLIC LIMITED COMPANY 1. The name of the Company is Nabriva Therapeutics public limited company. 2. The Company is a public limited company for the purposes of Part 17 of the Companies Act 2014. 3. The objects for which the Company is established are: 3.1. To carry on the business of a holding company and to coordinate the administration, finances and activities of any subsidiary companies or associated companies, to do all lawful acts and things whatsoever that are necessary or convenient in carrying on the business of such a holding company and in particular to carry on, i..."
08/17/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
Docs: "® , the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia . Nabriva Therapeutics is also developing CONTEPO™ for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections , including acute pyelonephritis."
07/06/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/29/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "® , the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia . Nabriva Therapeutics is also developing CONTEPO™ for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections , including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO ® in the United States and certain of its territories."
03/24/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
02/02/2022 8-K Quarterly results
01/18/2022 8-K Other Events  Interactive Data
01/14/2022 8-K Other Events  Interactive Data
01/10/2022 8-K Preliminary quarterly results
Docs: "Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021"
01/07/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
11/09/2021 8-K Quarterly results
Docs: "® , the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia . Nabriva Therapeutics is also developing CONTEPO™ for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections , including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO ® in the United States and certain of its territories."
09/27/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "* * * * * * 13 IN WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be duly executed as of day and year first above written.",
"DISCLOSURE SCHEDULES"
08/05/2021 8-K Quarterly results
07/30/2021 8-K Quarterly results
06/03/2021 8-K Quarterly results
05/25/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/15/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
02/26/2021 8-K Quarterly results
02/12/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy